Brief description of measure CMS819: Hospital Harm - Opioid-Related Adverse Events: This measure assesses the proportion of inpatient hospital encounters where patients ages 18 years of age or older have been administered an opioid medication and are subsequently administered an opioid antagonist (naloxone) within 12 hours, an indication of an opioid-related adverse event. This measure excludes opioid antagonist (naloxone) administration occurring in the operating room setting. Description of issue ​In February 2022, the U.S. FDA approved nalmefene hydrochloride injection to manage known or suspected opioid overdose and for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. Currently, the only opioid antagonist in the measure's 'Opioid Antagonist' value set is naloxone. Goal of review Obtain clinical feedback

Proposed solution ​Add concepts related to nalmefene to the 'Opioid Antagonist' value set (OID: 2.16.840.1.113762.1.4.1248.119). Rationale for change ​Adding nalmefene as an additional opioid antagonist could potentially capture more opioid-related adverse events (numerator) if nalmefene is used as the opioid antagonist following an opioid overdose during the encounter.